Whole Biome, a San Francisco, CA-based evidence-based microbiome company, secured $35m in Series B financing.
The round, which brings total funding to $57m, was led by existing investor Sequoia Capital with participation from True Ventures, Khosla Ventures, Mayo Foundation, AME Cloud Ventures and others. In conjunction with the funding, Sequoia Partner Roelof Botha has joined Whole Biome’s board of directors.
The company will use the new funds to advance the commercialization of its first patented product, expand its discovery pipeline and scale clinical trials for their novel microbiome interventions.
Founded in 2012 by Colleen Cutcliffe, chief executive officer, Whole Biome is developing a range of microbiome interventions targeting a variety of human health issues, starting with metabolic diseases, to help improve human health and wellbeing.
The company has built a proprietary microbiome discovery platform that identifies novel biochemical pathways and validates their potential for improving human health.
The company’s products are developed by applying scientific and clinical rigor to identify, hypothesize, test and measure novel strains and microbiome interventions.
Whole Biome plans to launch its first product for the dietary management of Type 2 Diabetes in early 2020.